---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: VMAT2 inhibitors"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: VMAT2 inhibitors. Topics: EHDN international guideline: first-line treatment of chorea, AAN evidence-based guideline on chorea (retired 2022): recommendation, AAN guideline status, German Neurological Society guideline: evidence for VMAT2 inhibitors and use of tetrabenazine, and 13 further topics. 17 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/vmat2-inhibitors"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: VMAT2 inhibitors

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 VMAT2 Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

### EHDN international guideline: first-line treatment of chorea

> “Drug treatment should be considered if chorea causes the patient distress or discomfort.”
> “Tetrabenazine is one of the first-line treatments for this symptom (Grade A)”
> “unless the patient suffers from not well-managed depression or suicidal thoughts.”
> “Deutetrabenazine may indeed be proposed as an alternative to tetrabenazine for the treatment of chorea in countries where the marketing authorization is already obtained, like in the USA.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.1-2"></a>

### AAN evidence-based guideline on chorea (retired 2022): recommendation

> “If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit. Occurrence of adverse events should be discussed and monitored, particularly depression/suicidality and parkinsonism with tetrabenazine and elevated liver enzymes with riluzole.”

Source: [Armstrong and Miyasaki (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413759/)

<a id="topic-2.2.2.1.1-3"></a>

### AAN guideline status

> “This guideline is retired.”
> “Retired on July 16, 2022.”

Source: [American Academy of Neurology (2022)](https://www.aan.com/Guidelines/home/GuidelineDetail/558)

<a id="topic-2.2.2.1.1-4"></a>

### German Neurological Society guideline: evidence for VMAT2 inhibitors and use of tetrabenazine

> “The quality of data from RCTs is currently best for VMAT2 inhibitors”
> “The use of tetrabenazine (in combination or as monotherapy) is recommended if treatment with tiapride is either not tolerated or not efficacious.”

Source: [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)

<a id="topic-2.2.2.1.1-5"></a>

### MDS evidence-based review of treatments for Huntington's disease

> “These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea.”
> “Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms.”

Source: [Ferreira et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34842303/)

<a id="topic-2.2.2.1.1-6"></a>

### Cochrane review of symptomatic treatments

> “22 trials (1254 participants) were included.”
> “Only tetrabenazine showed a clear efficacy for the control of chorea. The remaining pharmacological interventions revealed no clear effectiveness.”

Source: [Mestre et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19588393/)

<a id="topic-2.2.2.1.1-7"></a>

### HSG expert consensus: classes used for chorea in North American practice

> “Despite the negative impact chorea can have on many aspects of day-to-day life, pharmacologic treatment remains underutilized in clinical practice.”
> “The two most common medication classes used to suppress chorea are vesicular monoamine transporter 2 (VMAT2) inhibitors and antipsychotics.”

Source: [Furr Stimming et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42446188/)

<a id="topic-2.2.2.1.1-8"></a>

### Tetrabenazine: FDA-approved indication and boxed warning

> “XENAZINE is indicated for the treatment of chorea associated with Huntington’s disease.”
> “XENAZINE can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Anyone considering the use of XENAZINE must balance the risks of depression and suicidality with the clinical need for control of chorea.”

Source: [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda)

<a id="topic-2.2.2.1.1-9"></a>

### Tetrabenazine: label efficacy and functional outcomes in Study 1

> “As shown in Figure 1, Total Chorea Scores for patients in the drug group declined by an estimated 5.0 units during maintenance therapy (average of Week 9 and Week 12 scores versus baseline), compared to an estimated 1.5 units in the placebo group. The treatment effect of 3.5 units was statistically significant. At the Week 13 follow-up in Study 1 (1 week after discontinuation of the study medication), the Total Chorea Scores of patients receiving XENAZINE returned to baseline.”
> “In general, measures of functional capacity and cognition showed no difference between XENAZINE and placebo.”

Source: [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda)

<a id="topic-2.2.2.1.1-10"></a>

### Tetrabenazine: depression and sedation in the placebo-controlled trial

> “In a 12-week, double-blind, placebo-controlled study in patients with chorea associated with Huntington’s disease, 10 of 54 patients (19%) treated with XENAZINE were reported to have an adverse event of depression or worsening depression compared to none of the 30 placebo-treated patients.”
> “Sedation is the most common dose-limiting adverse reaction of XENAZINE.”

Source: [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda)

<a id="topic-2.2.2.1.1-11"></a>

### Tetrabenazine: TETRA-HD randomized trial

> “The authors randomized 84 ambulatory patients with HD to receive TBZ (n = 54) or placebo (n = 30) for 12 weeks.”
> “There were five study withdrawals in the TBZ group and five serious adverse events (SAEs) in four subjects (drowning suicide, complicated fall, restlessness/suicidal ideation, and breast cancer) compared with one withdrawal and no SAEs in the placebo group.”

Source: [Huntington Study Group (2006)](https://pubmed.ncbi.nlm.nih.gov/16476934/)

<a id="topic-2.2.2.1.1-12"></a>

### Deutetrabenazine: FDA boxed warning and label efficacy

> “AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease.”
> “Total Maximal Chorea Scores for patients receiving AUSTEDO improved by approximately 4.4 units from baseline to the maintenance period (average of Week 9 and Week 12), compared to approximately 1.9 units in the placebo group. The treatment effect of -2.5 units was statistically significant (p<0.0001).”

Source: [DailyMed AUSTEDO prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0)

<a id="topic-2.2.2.1.1-13"></a>

### Deutetrabenazine: First-HD randomized trial

> “Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002).”
> “Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety.”

Source: [Huntington Study Group (2016)](https://pubmed.ncbi.nlm.nih.gov/27380342/)

<a id="topic-2.2.2.1.1-14"></a>

### Valbenazine: FDA boxed warning and label efficacy

> “VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease.”
> “The mean change in Total Maximal Chorea scores for patients receiving INGREZZA improved by 4.6 units (LS mean) from baseline to the end of the treatment period (average of Week 10 and Week 12), compared to 1.4 units in the placebo group. The treatment effect of -3.2 units was statistically significant (p<0.0001)”

Source: [DailyMed INGREZZA prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417)

<a id="topic-2.2.2.1.1-15"></a>

### Valbenazine: parkinsonism in Huntington's disease

> “Drug-induced parkinsonism has the potential to cause more functional disability than untreated chorea for some patients with Huntington’s disease.”

Source: [DailyMed INGREZZA prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417)

<a id="topic-2.2.2.1.1-16"></a>

### Valbenazine: KINECT-HD randomized trial

> “Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo) and 127 were included in the safety-analysis set (64 assigned to valbenazine, 63 assigned to placebo).”
> “No suicidal behaviour or worsening of suicidal ideation was reported in participants treated with valbenazine.”

Source: [Furr Stimming et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37210099/)

<a id="topic-2.2.2.1.1-17"></a>

### HDSA physician's guide: indications for pharmacologic treatment of chorea

> “Symptoms that indicate the need for possible pharmacologic management of chorea include muscle pain, frequent dropping of items, repetitive injuries, falls associated with chorea of the trunk and limbs, poor sleep, and weight loss.”

Source: [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)

Additional sources: [Reilmann (2013)](https://pubmed.ncbi.nlm.nih.gov/23674480/); [Frank et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39825184/); [Coppen and Roos (2017)](https://pubmed.ncbi.nlm.nih.gov/27988871/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
